Duo-Tablet 5/1000 mg
Metformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
MFDS item code 201503483 · Approved 2015.05.29
This product's status changed to Expired on 2024.11.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help adult patients with type 2 diabetes who are suitable for combination therapy with Dapagliflozin and Metformin in controlling blood sugar levels. Particularly, in patients whose blood sugar is not well controlled and who have cardiovascular disease or risk factors, it is advisable to refer to expert guidelines on how Dapagliflozin affects cardiovascular events. Overall, this medication effectively improves blood sugar control in patients with type 2 diabetes.
The dose of this product should be individualized based on the patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This product is generally administered once daily with the evening meal. The maximum dose of this product is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients with no previous history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no previous history of antidiabetic drug therapy, the recommended starting dose of this product is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse effects of metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this product should provide the patient's current metformin dose or the nearest appropriate therapeutic dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjusted appropriately. In patients switching from combination therapy with dapagliflozin and metformin to this product, treatment may be initiated at the existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjusted appropriately. When this product is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this product have not been specifically evaluated in patients switched from other antihyperglycemic agents. Because such a change may result in altered glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This product must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this product may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this product, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this product is not recommended in patients with eGFR < 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to < 45 mL/min/1.73m2, this product should be discontinued immediately. Renal function should be evaluated every 3~6 months. Elderly patients Metformin is excreted by the kidneys, and renal function is likely to decline in elderly patients; therefore, this product should be used with caution with increasing age (see Precautions for Use, 9. Use in Elderly Patients).
This medication is used for the treatment of diabetes and helps control blood sugar. However, this medication can very rarely cause a dangerous condition called severe lactic acidosis, thus caution is advised. When used with other diabetes medications, hypoglycemic symptoms may occur, so it should be used with care. It should not be administered to patients with poor kidney function, dehydration, severe infections, or heart problems. Pregnant or breastfeeding women, as well as patients with certain genetic disorders, should not use this medication. Elderly patients or those with impaired kidney function should have their kidney function regularly tested while using this medication, and their fluid status should be closely monitored. Genital infections or urinary tract infections can occur during the use of this medication, so if symptoms arise, consult a physician immediately. Also, hypoglycemic symptoms may occur, so dosage adjustment may be necessary when used in conjunction with insulin or sulfonylureas. This medication can lower vitamin B12 levels, so long-term users are advised to undergo vitamin B12 testing. Alcohol consumption can increase the risk of lactic acidosis, so excessive drinking should be avoided while on this medication. Before surgery or radiation tests, this medication should be temporarily discontinued, and it should be restarted only after confirming normal kidney function. In cases of overdose, seek medical attention immediately for appropriate treatment, and dialysis may be required. This medication should be kept out of reach of children and stored in its original container for safety. Caution is advised while driving or operating machinery, as dizziness may occur.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it is best stored at room temperature between 1°C and 30°C, avoiding very hot or very cold places.
Pink to dark pink, biconvex, oval film-coated tablets
30 tablets (6 tablets x 5) / box
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Metformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
Metformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
YouYoung Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
Yuyoung Pharmaceutical Co., Ltd.
CombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
CombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.